CoChat
Sign Up
Cited by 106Lung Cancer Treatments and MutationsCancer Genomics and DiagnosticsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Minari, R., Bordi, P., Del Re, M., Facchinetti, F., Mazzoni, F., Barbieri, F., Camerini, A., Comin, C.E., Gnetti, L., Azzoni, C., Nizzoli, R., Bortesi, B., Rofi, E., Petreni, P., Campanini, N., Rossi, G., Danesi, R., Tiseo, M.·2018·Lung Cancer
DOI 10.1016/j.lungcan.2017.11.011
Open this paper in CoChat — free account

Abstract

Objectives EGFR T790M mutation is the most common mechanism of resistance to first-/second-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) and could be overcome by third-generation EGFR-TKIs, such as osimertinib. Liquid biopsy, a non-invasive technique used to test the presence of the resistant mutation, may help avoiding tissue re-biopsy. However, analysing only circulating-free DNA, information about other less frequent and coexisting resistance mechanisms may remain unrevealed.Materials and methods All patients reported in this series participated in the ASTRIS trial, a real world treatment study testing the efficacy of osimertinib (80mg os die) in advanced T790M-positive NSCLC progressed to prior EGFR-TKI. Patients were considered eligible to osimertinib if T790M positive on tissue or plasma samples. In our patients, EGFR molecular testing on blood sample was conducted with digital droplet PCR (ddPCR).Results We report our experience of five patients treated with osimertinib after T790M detection on liquid biopsy that presented a disease progression at first tumor assessment mediated by SCLC transformation, as evidenced at tissue re-biopsies. All patients showed low ratio T790M/activating mutation in the blood before osimertinib (lower than 0.03). For three patients, EGFR mutational analysis was T790M-negative when re-assessed by using a less sensitive method (therascreen®) on the same liquid biopsy sample analysed by ddPCR before osimertinib therapy.Conclusion Although liquid biopsy is a relevant tool to diagnose T790M presence in NSCLC patients resistant to EGFR-TKI, in case of a low ratio T790M/activating mutation, tissue biopsy should be considered to exclude the presence of SCLC transformation and/or other concomitant resistance mechanisms.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2017.11.011

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 25 references

Cited by

Sorted by citations

Items 101–106 of 106

Related

See all

Metadata

Authors
Minari, R., Bordi, P., Del Re, M., Facchinetti, F., Mazzoni, F., Barbieri, F., Camerini, A., Comin, C. E., Gnetti, L., Azzoni, C., Nizzoli, R., Bortesi, B., Rofi, E., Petreni, P., Campanini, N., Rossi, G., Danesi, R., & Tiseo, M.
Affiliations
  • University of Parma (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • Azienda Ospedaliero-Universitaria di Modena (IT)
  • Ospedale Versilia (IT)
  • University of Florence (IT)
  • Ospedale di Parma (IT)
  • University of Pisa (IT)
  • Azienda USL della Valle d’Aosta (IT)
Corresponding author
Tiseo, M.
ORCID
Venue
Lung Cancer
Publisher
Elsevier BV
Published
2018-01
Volume
115
Pages
21-27
ISSN
0169-5002 (ISSN-L)
DOI
10.1016/j.lungcan.2017.11.011
OpenAlex
W2769241338
Cited by
105
References
25
Citations by year
2026: 4 · 2025: 6 · 2024: 10 · 2023: 8 · 2022: 11 · 2021: 18 · 2020: 16 · 2019: 18 · 2018: 14
FWCI
10.86
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Lung Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
osimertinib, T790M mutation, small cell lung cancer transformation, liquid biopsy, circulating tumor DNA, EGFR tyrosine kinase inhibitors, treatment resistance, droplet digital PCR, non-small cell lung cancer
MeSH terms
Acrylamides, Aged, Aniline Compounds, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Cell Transformation, Neoplastic, DNA Mutational Analysis, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Piperazines, Pyrimidines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review